Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Brechbiel Website

Martin W. Brechbiel, Ph.D.

Selected Publications

1)  Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.
Br. J. Cancer. 108: 2013-20, 2013.
[Journal]
2)  Milenic DE, Baidoo KE, Shih JH, Wong KJ, Brechbiel MW.
Evaluation of platinum chemotherapy in combination with HER2-targeted a-particle radiation.
Cancer Biother. Radiopharm. 28: 441-9, 2013.
[Journal]
3)  Guérard F, Lee YS, Tripier R, Szajek LP, Deschamps JR, Brechbiel MW.
Investigation of Zr(IV) and 89Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging.
Chem. Commun. (Camb.). 49: 1002-4, 2013.
[Journal]
4)  Baidoo KE, Milenic DE, Brechbiel MW.
Methodology for labeling proteins and peptides with lead-212 (212Pb).
Nucl. Med. Biol. 40: 592-9, 2013.
[Journal]
5)  Burvenich IJ, Lee FT, Cartwright GA, O'Keefe GJ, Makris D, Cao D, Gong S, Chueh AC, Mariadason JM, Brechbiel MW, Beckman RA, Fujiwara K, von Roemeling R, Scott AM.
Molecular Imaging of Death Receptor 5 Occupancy and Saturation Kinetics In Vivo by Humanized Monoclonal Antibody CS-1008.
Clin. Cancer Res. 19: 5984-93, 2013.
[Journal]
6)  Baidoo KE, Yong K, Brechbiel MW.
Molecular pathways: targeted a-particle radiation therapy.
Clin. Cancer Res. 19: 530-7, 2013.
[Journal]
7)  Nayak TK, Bernardo M, Milenic DE, Choyke PL, Brechbiel MW.
Orthotopic Pleural Mesothelioma in Mice: SPECT/CT and MR Imaging with HER1- and HER2-targeted Radiolabeled Antibodies.
Radiology. 267: 173-82, 2013.
[Journal]
8)  Kang CS, Song HA, Milenic DE, Baidoo KE, Brechbiel MW, Chong H.
Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using (212)Bi and (213)Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies.
Nucl. Med. Biol. [Epub ahead of print], 2013.
[Journal]
9)  Guérard F, Gestin JF, Brechbiel MW.
Production of [(211)At]-astatinated radiopharmaceuticals and applications in targeted a-particle therapy.
Cancer Biother. Radiopharm. 28: 1-20, 2013.
[Journal]
10)  Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
Sensitization of tumor to (212)pb radioimmunotherapy by gemcitabine involves initial abrogation of g2 arrest and blocked DNA damage repair by interference with rad51.
Int. J. Radiat. Oncol. Biol. Phys. 85: 1119-26, 2013.
[Journal]
11)  Bumb A, Sarkar SK, Billington N, Brechbiel MW, Neuman KC.
Silica encapsulation of fluorescent nanodiamonds for colloidal stability and facile surface functionalization.
J. Am. Chem. Soc. 2013.
[Journal]
12)  Lee SM, Tsai DH, Hackley VA, Brechbiel MW, Cook RF.
Surface-engineered nanomaterials as X-ray absorbing adjuvant agents for Auger-mediated chemo-radiation.
Nanoscale. 5: 5252-6, 2013.
[Journal]
13)  Nwe K, Kim YS, Milenic DE, Baidoo KE, Brechbiel MW.
(111)In- and (203)Pb-Labeled Cyclic RGD Peptide Conjugate as an a(v)ß(3) Integrin-Binding Radiotracer.
J Labelled Comp Radiopharm. 55: 423-426, 2012.
[Journal]
14)  Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW.
(212)Pb-radioimmunotherapy induces G(2) cell-cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease.
Mol. Cancer Ther. 11: 639-48, 2012.
[Journal]
15)  Kim YS, Brechbiel MW.
An overview of targeted alpha therapy.
Tumour Biol. 33: 573-90, 2012.
[Journal]
16)  Huang CH, Nwe K, Al Zaki A, Brechbiel MW, Tsourkas A.
Biodegradable polydisulfide dendrimer nanoclusters as MRI contrast agents.
ACS Nano. 6: 9416-24, 2012.
[Journal]
17)  Zhou Y, Baidoo KE, Brechbiel MW.
Mapping biological behaviors by application of longer-lived positron emitting radionuclides.
Adv. Drug Deliv. Rev. [Epub ahead of print], 2012.
[Journal]
18)  Nayak TK, Garmestani K, Milenic DE, Brechbiel MW.
PET and MRI of metastatic peritoneal and pulmonary colorectal cancer in mice with human epidermal growth factor receptor 1-targeted 89Zr-labeled panitumumab.
J. Nucl. Med. 53: 113-20, 2012.
[Journal]
19)  Nwe K, Milenic DE, Ray GL, Kim YS, Brechbiel MW.
Preparation of cystamine core dendrimer and antibody-dendrimer conjugates for MRI angiography.
Mol. Pharm. 9: 374-81, 2012.
[Journal]
20)  Kim YS, Nwe K, Milenic DE, Brechbiel MW, Satz S, Baidoo KE.
Synthesis and characterization of avß3-targeting peptidomimetic chelate conjugates for PET and SPECT imaging.
Bioorg. Med. Chem. Lett. 22: 5517-22, 2012.
[Journal]
21)  Nayak TK, Brechbiel MW.
86Y based PET radiopharmaceuticals: radiochemistry and biological applications.
Med Chem. 7: 380-8, 2011.
[Journal]
22)  Song HA, Kang CS, Baidoo KE, Milenic DE, Chen Y, Dai A, Brechbiel MW, Chong H.
Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α-Radioimmunotherapy Applications.
Bioconjug Chem. 22: 1128-35, 2011.
[Journal]
23)  Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW.
HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
PLoS ONE. 6: e18198, 2011.
[Journal]
24)  Wong KJ, Baidoo KE, Nayak TK, Garmestani K, Brechbiel MW, Milenic DE.
In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers.
EJNMMI Res. 1, 2011.
[Journal]
25)  Ray GL, Baidoo KE, Keller LM, Albert PS, Brechbiel MW, Milenic DE.
Pre-Clinical Assessment of Lu-Labeled Trastuzumab Targeting HER2 for Treatment and Management of Cancer Patients with Disseminated Intraperitoneal Disease.
Pharmaceuticals. 5: 1-15, 2011.
[Journal]
26)  Nwe K, Milenic D, Bryant LH, Regino CA, Brechbiel MW.
Preparation, characterization and in vivo assessment of Gd-albumin and Gd-dendrimer conjugates as intravascular contrast-enhancing agents for MRI.
J. Inorg. Biochem. 105: 722-7, 2011.
[Journal]
27)  Bumb A, Sarkar SK, Wu XS, Brechbiel MW, Neuman KC.
Quantitative characterization of fluorophores in multi-component nanoprobes by single-molecule fluorescence.
Biomed Opt Express. 2: 2761-9, 2011.
[Journal]
28)  Dadwal M, Kang CS, Song HA, Sun X, Dai A, Baidoo KE, Brechbiel MW, Chong HS.
Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates.
Bioorg. Med. Chem. Lett. 21: 7513-5, 2011.
[Journal]
29)  Yong K, Brechbiel MW.
Towards translation of (212)Pb as a clinical therapeutic; getting the lead in!.
Dalton Trans. 40: 6068-76, 2011.
[Journal]
30)  Nwe K, Bernardo M, Regino CA, Williams M, Brechbiel MW.
Comparison of MRI properties between derivatized DTPA and DOTA gadolinium-dendrimer conjugates.
Bioorg. Med. Chem. 18: 5925-31, 2010.
[Journal]
31)  Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW.
Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72.
Cancer. 116: 1059-66, 2010.
[Journal]
32)  Villaraza AJ, Milenic DE, Brechbiel MW.
Improved speciation characteristics of PEGylated indocyanine green-labeled Panitumumab: revisiting the solution and spectroscopic properties of a near-infrared emitting anti-HER1 antibody for optical imaging of cancer.
Bioconjug. Chem. 21: 2305-12, 2010.
[Journal]
33)  Bumb A, Brechbiel MW, Choyke P.
Macromolecular and dendrimer-based magnetic resonance contrast agents.
Acta Radiol. 51: 751-67, 2010.
[Journal]
34)  Villaraza AJ, Bumb A, Brechbiel MW.
Macromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.
Chem. Rev. 110: 2921-59, 2010.
[Journal]
35)  Sena LM, Fishman SJ, Jenkins KJ, Xu H, Brechbiel MW, Regino CA, Kosaka N, Bernardo M, Choyke PL, Kobayashi H.
Magnetic resonance lymphangiography with a nano-sized gadolinium-labeled dendrimer in small and large animal models.
Nanomedicine. 5: 1183-91, 2010.
[Journal]
36)  Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW.
PET imaging of HER1-expressing xenografts in mice with (86)Y-CHX-A''-DTPA-cetuximab.
Eur. J. Nucl. Med. Mol. Imaging. 37: 1368-76, 2010.
[Journal]
37)  Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.
PET imaging of tumor angiogenesis in mice with VEGF-A targeted (86)Y-CHX-A''-DTPA-bevacizumab.
Int J Cancer. 128: 920-6, 2010.
[Journal]
38)  Nwe K, Bryant LH, Brechbiel MW.
Poly(amidoamine) Dendrimer Based MRI Contrast Agents Exhibiting Enhanced Relaxivities Derived via Metal Preligation Techniques.
Bioconjug. Chem. 21: 1014-7, 2010.
[Journal]
39)  Bumb A, Regino CA, Perkins MR, Bernardo M, Ogawa M, Fugger L, Choyke PL, Dobson PJ, Brechbiel MW.
Preparation and characterization of a magnetic and optical dual-modality molecular probe.
Nanotechnology. 21: 175704, 2010.
[Journal]
40)  Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.
Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
J. Nucl. Med. 51: 942-50, 2010.
[Journal]
41)  Milenic DE, Wong KJ, Baidoo KE, Nayak TK, Regino CA, Garmestani K, Brechbiel MW.
Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
MAbs. 2: 550-64, 2010.
[Journal]
42)  Bumb A, Regino CA, Egen JG, Bernardo M, Dobson PJ, Germain RN, Choyke PL, Brechbiel MW.
Trafficking of a Dual-Modality Magnetic Resonance and Fluorescence Imaging Superparamagnetic Iron Oxide-Based Nanoprobe to Lymph Nodes.
Mol Imaging Biol. 2010.
[Journal]
43)  Nwe K, Xu H, Regino CA, Bernardo M, Ileva L, Riffle L, Wong KJ, Brechbiel MW.
A new approach in the preparation of dendrimer-based bifunctional diethylenetriaminepentaacetic acid MR contrast agent derivatives.
Bioconjug. Chem. 20: 1412-8, 2009.
[Journal]
44)  Boswell CA, Regino CA, Baidoo KE, Wong KJ, Milenic DE, Kelley JA, Lai CC, Brechbiel MW.
A novel side-bridged hybrid phosphonate/acetate pendant cyclam: synthesis, characterization, and 64Cu small animal PET imaging.
Bioorg. Med. Chem. 17: 548-52, 2009.
[Journal]
45)  Nwe K, Brechbiel MW.
Growing applications of.
Cancer Biother. Radiopharm. 24: 289-302, 2009.
[Journal]
46)  Wei L, Zhang X, Gallazzi F, Miao Y, Jin X, Brechbiel MW, Xu H, Clifford T, Welch MJ, Lewis JS, Quinn TP.
Melanoma imaging using 111In-, 86Y- and 68Ga-labeled CHX-A''-Re(Arg11)CCMSH.
Nucl. Med. Biol. 36: 345-54, 2009.
[Journal]
47)  Herbertson RA, Tebbutt NC, Lee FT, MacFarlane DJ, Chappell B, Micallef N, Lee ST, Saunder T, Hopkins W, Smyth FE, Wyld DK, Bellen J, Sonnichsen DS, Brechbiel MW, Murone C, Scott AM.
Phase I biodistribution and pharmacokinetic study of Lewis Y-targeting immunoconjugate CMD-193 in patients with advanced epithelial cancers.
Clin. Cancer Res. 15: 6709-15, 2009.
[Journal]
48)  Regino CA, Wong KJ, Milenic DE, Holmes EH, Garmestani K, Choyke PL, Brechbiel MW.
Preclinical evaluation of a monoclonal antibody (3C6) specific for prostate-specific membrane antigen.
Current radiopharmaceuticals. 2: 9-17, 2009.
[Journal]
49)  Ray GL, Baidoo KE, Wong KJ, Williams M, Garmestani K, Brechbiel MW, Milenic DE.
Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.
Br. J. Pharmacol. 157: 1541-8, 2009.
[Journal]
50)  Zhang M, Yao Z, Garmestani K, Yu S, Goldman CK, Paik CH, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Preclinical evaluation of an anti-CD25 monoclonal antibody, 7G7/B6, armed with the beta-emitter, yttrium-90, as a radioimmunotherapeutic agent for treating lymphoma.
Cancer Biother. Radiopharm. 24: 303-9, 2009.
[Journal]
51)  Nayak TK, Brechbiel MW.
Radioimmunoimaging with Longer-Lived Positron-Emitting Radionuclides: Potentials and Challenges.
Bioconjug. Chem. 20: 825-41, 2009.
[Journal]
52)  Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM.
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Prostate. 69: 92-104, 2009.
[Journal]
53)  Xu H, Eck PK, Baidoo KE, Choyke PL, Brechbiel MW.
Toward preparation of antibody-based imaging probe libraries for dual-modality positron emission tomography and fluorescence imaging.
Bioorg. Med. Chem. 2009.
[Journal]
54)  Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW.
Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.
Cancer Biother. Radiopharm. 23: 619-31, 2008.
[Journal]
55)  Chong HS, Lim S, Baidoo KE, Milenic DE, Ma X, Jia F, Song HA, Brechbiel MW, Lewis MR.
Synthesis and biological evaluation of a novel decadentate ligand DEPA.
Bioorg. Med. Chem. Lett. 2008.
[Journal]
56)  Kelly MP, Lee FT, Tahtis K, Power BE, Smyth FE, Brechbiel MW, Hudson PJ, Scott AM.
Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
Cancer Biother. Radiopharm. 23: 411-23, 2008.
[Journal]
57)  Regino CA, Walbridge S, Bernardo M, Wong KJ, Johnson D, Lonser R, Oldfield EH, Choyke PL, Brechbiel MW.
A dual CT-MR dendrimer contrast agent as a surrogate marker for convection-enhanced delivery of intracerebral macromolecular therapeutic agents.
Contrast Media Mol Imaging. 3: 2-8, 2008.
[Journal]
58)  Xu H, Baidoo KE, Wong KJ, Brechbiel MW.
A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules.
Bioorg. Med. Chem. Lett. 18: 2679-83, 2008.
[Journal]
59)  Brechbiel MW.
Bifunctional chelates for metal nuclides.
Q J Nucl Med Mol Imaging. 52: 166-73, 2008.
[Journal]
60)  Robinson MK, Shaller C, Garmestani K, Plascjak PS, Hodge KM, Yuan QA, Marks JD, Waldmann TA, Brechbiel MW, Adams GP.
Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies.
Clin. Cancer Res. 14: 875-82, 2008.
[Journal]
61)  Tolmachev V, Xu H, Wallberg H, Ahlgren S, Hjertman M, Sjoberg A, Sandstrom M, Abrahmsen L, Brechbiel MW, Orlova A.
Evaluation of a Maleimido Derivative of CHX-A'' DTPA for Site-Specific Labeling of Affibody Molecules.
Bioconjug. Chem. E-pub ahead of print, 2008.
[Journal]
62)  Vallera DA, Stish BJ, Shu Y, Chen H, Saluja A, Buchsbaum DJ, Vickers SM.
Genetically designing a more potent antipancreatic cancer agent by simultaneously co-targeting human IL13 and EGF receptors in a mouse xenograft model.
Gut. 57: 634-41, 2008.
[Journal]
63)  Childers ML, Cho J, Regino CA, Brechbiel MW, DiPasquale AG, Rheingold AL, Torti SV, Torti FM, Planalp RP.
Influence of ligand structure on Fe(II) spin-state and redox rate in cytotoxic tripodal chelators.
J. Inorg. Biochem. 102: 150-6, 2008.
[Journal]
64)  Milenic DE, Garmestani K, Brady ED, Baidoo KE, Albert PS, Wong KJ, Flynn J, Brechbiel MW.
Multimodality therapy: potentiation of high linear energy transfer radiation with Paclitaxel for the treatment of disseminated peritoneal disease.
Clin. Cancer Res. 14: 5108-15, 2008.
[Journal]
65)  Chong HS, Song HA, Ma X, Milenic DE, Brady ED, Lim S, Lee H, Baidoo K, Cheng D, Brechbiel MW.
Novel bimodal bifunctional ligands for radioimmunotherapy and targeted MRI.
Bioconjug. Chem. 19: 1439-47, 2008.
[Journal]
66)  Hariri G, Zhang Y, Fu A, Han Z, Brechbiel M, Tantawy MN, Peterson TE, Mernaugh R, Hallahan D.
Radiation-guided P-selectin antibody targeted to lung cancer.
Ann Biomed Eng. 36: 821-30, 2008.
[Journal]
67)  Chong HS, Ma X, Le T, Kwamena B, Milenic DE, Brady ED, Song HA, Brechbiel MW.
Rational design and generation of a bimodal bifunctional ligand for antibody-targeted radiation cancer therapy.
J. Med. Chem. 51: 118-25, 2008.
[Journal]
68)  Wilbur DS, Hamlin DK, Chyan MK, Brechbiel MW.
Streptavidin in antibody pretargeting. 5. chemical modification of recombinant streptavidin for labeling with the alpha-particle-emitting radionuclides 213Bi and 211At.
Bioconjug. Chem. 19: 158-70, 2008.
[Journal]
69)  Boswell CA, Regino CA, Baidoo KE, Wong KJ, Bumb A, Xu H, Milenic DE, Kelley JA, Lai CC, Brechbiel MW.
Synthesis of a cross-bridged cyclam derivative for peptide conjugation and 64Cu radiolabeling.
Bioconjug. Chem. 19: 1476-84, 2008.
[Journal]
70)  Boswell CA, Eck PK, Regino CA, Bernardo M, Wong KJ, Milenic DE, Choyke PL, Brechbiel MW.
Synthesis, Characterization, and Biological Evaluation of Integrin alphavbeta3-Targeted PAMAM Dendrimers.
Mol. Pharm. 2008.
[Journal]
71)  Koyama Y, Talanov VS, Bernardo M, Hama Y, Regino CA, Brechbiel MW, Choyke PL, Kobayashi H.
A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice.
J Magn Reson Imaging. 25: 866-71, 2007.
[Journal]
72)  Scott AM, Tebbutt N, Lee FT, Cavicchiolo T, Liu Z, Gill S, Poon AM, Hopkins W, Smyth FE, Murone C, MacGregor D, Papenfuss AT, Chappell B, Saunder TH, Brechbiel MW, Davis ID, Murphy R, Chong G, Hoffman EW, Old LJ.
A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen.
Clin. Cancer Res. 13: 3286-92, 2007.
[Journal]
73)  Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z, Skrinos E, Murone C, Saunder TH, Chappell B, Papenfuss AT, Poon AM, Hopkins W, Smyth FE, MacGregor D, Cher LM, Jungbluth AA, Ritter G, Brechbiel MW, Murphy R, Burgess AW, Hoffman EW, Johns TG, Old LJ.
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
Proc. Natl. Acad. Sci. U.S.A. 104: 4071-6, 2007.
[Journal]
74)  Xu H, Baidoo K, Gunn AJ, Boswell CA, Milenic DE, Choyke PL, Brechbiel MW.
Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.
J. Med. Chem. 50: 4759-65, 2007.
[Journal]
75)  Boswell CA, Brechbiel MW.
Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view.
Nucl. Med. Biol. 34: 757-78, 2007.
[Journal]
76)  Zhang M, Yao Z, Patel H, Garmestani K, Zhang Z, Talanov VS, Plascjak PS, Goldman CK, Janik JE, Brechbiel MW, Waldmann TA.
Effective therapy of murine models of human leukemia and lymphoma with radiolabeled anti-CD30 antibody, HeFi-1.
Proc. Natl. Acad. Sci. U.S.A. 104: 8444-8, 2007.
[Journal]
77)  Keller L, Boswell C, Milenic D, Brady D, Brechbiel M.
Monoclonal Antibody Targeted Radiation Cancer Therapy, in "Biologics in General Medicine", eds. Radeke, H. H., Boehncke, W.-H.
Springer. N/A, 2007.
[Journal]
78)  Hama Y, Bernardo M, Regino CA, Koyama Y, Brechbiel MW, Krishna MC, Choyke PL, Kobayashi H.
MR lymphangiography using dendrimer-based contrast agents: a comparison at 1.5T and 3.0T.
J Magn Reson Imaging. 57: 431-6, 2007.
[Journal]
79)  Barrett T, Brechbiel M, Bernardo M, Choyke PL.
MRI of tumor angiogenesis.
J Magn Reson Imaging. 26: 235-49, 2007.
[Journal]
80)  Chong HS, Mhaske S, Lin M, Bhuniya S, Song HA, Brechbiel MW, Sun X.
Novel synthetic ligands for targeted PET imaging and radiotherapy of copper.
Bioorg. Med. Chem. Lett. 17: 6107-10, 2007.
[Journal]
81)  Song EY, Abbas Rizvi SM, Qu CF, Raja C, Brechbiel MW, Morgenstern A, Apostolidis C, Allen BJ.
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer.
Cancer Biol. Ther. 6: 898-904, 2007.
[Journal]
82)  Milenic DE, Garmestani K, Brady ED, Albert PS, Abdulla A, Flynn J, Brechbiel MW.
Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
Clin. Cancer Res. 13: 1926-35, 2007.
[Journal]
83)  Xu H, Regino CA, Koyama Y, Hama Y, Gunn AJ, Bernardo M, Kobayashi H, Choyke PL, Brechbiel MW.
Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging.
Bioconjug. Chem. 18: 1474-82, 2007.
[Journal]
84)  Kelly MP, Lee FT, Tahtis K, Smyth FE, Brechbiel MW, Scott AM.
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Clin. Cancer Res. 13: 5604s-5612s, 2007.
[Journal]
85)  Vallera DA, Sicheneder AR, Taras EP, Brechbiel MW, Vallera JA, Panoskaltsis-Mortari A, Burns LJ.
Radiotherapy of CD45-expressing Daudi tumors in nude mice with yttrium-90-labeled, PEGylated anti-CD45 antibody.
Cancer Biother. Radiopharm. 22: 488-500, 2007.
[Journal]
86)  Brechbiel MW.
Targeted alpha-therapy: past, present, future?.
Dalton Trans. 4918-28, 2007.
[Journal]
87)  Gunn AJ, Brechbiel MW, Choyke PL.
The emerging role of molecular imaging and targeted therapeutics in peritoneal carcinomatosis.
Expert Opin Drug Deliv. 4: 389-402, 2007.
[Journal]
88)  Xu H, Regino CA, Bernardo M, Koyama Y, Kobayashi H, Choyke PL, Brechbiel MW.
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry.
J. Med. Chem. 50: 3185-93, 2007.
[Journal]
89)  Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, de Jong M, Garmestani K, Brechbiel MW, Kvols LK.
213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
Clin. Cancer Res. 12: 897-903, 2006.
[Journal]
90)  Kobayashi H, Kawamoto S, Bernardo M, Brechbiel MW, Knopp MV, Choyke PL.
Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging.
J. Med. Chem. 111: 343-51, 2006.
[Journal]
91)  Kobayashi H, Kawamoto S, Bernardo M, Brechbiel MW, Knopp MV, Choyke PL.
Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging.
J Control Release. 111: 343-51, 2006.
[Journal]
92)  Talanov VS, Regino CA, Kobayashi H, Bernardo M, Choyke PL, Brechbiel MW.
Dendrimer-based nanoprobe for dual modality magnetic resonance and fluorescence imaging.
Nano Lett. 6: 1459-63, 2006.
[Journal]
93)  Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA.
Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.
Blood. 1, 2006.
[Journal]
94)  Zhang Z, Zhang M, Garmestani K, Talanov VS, Plascjak PS, Beck B, Goldman CK, Brechbiel MW, Waldmann TA.
Effective treatment of a murine model of adult T cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizmab) directed towards CD25.
Blood. 49: 1, 2006.
[Journal]
95)  Kelly MP, Lee FT, Smyth FE, Brechbiel MW, Scott AM.
Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
J. Nucl. Med. 47: 716-25, 2006.
[Journal]
96)  Dear JW, Kobayashi H, Brechbiel MW, Star RA.
Imaging acute renal failure with polyamine dendrimer-based MRI contrast agents.
J. Med. Chem. 103: c45-9, 2006.
[Journal]
97)  Chong H, Milenic DE, Garmestani K, Brady ED, Arora H, Pfiester C, Brechbiel MW.
In vitro and in vivo evaluation of novel ligands for radioimmunotherapy.
Nucl Med Biol. 33: 459-467, 2006.
[Journal]
98)  Barrett T, Kobayashi H, Brechbiel M, Choyke PL.
Macromolecular MRI contrast agents for imaging tumor angiogenesis.
Eur J Radiol. 60: 353-66, 2006.
[Journal]
99)  Wong RS, Brechbiel MW.
National cancer institute perspectives.
Int. J. Radiat. Oncol. Biol. Phys. 66: S96-9, 2006.
[Journal]
100)  Talanov VS, Garmestani K, Regino CA, Milenic DE, Plascjak PS, Waldmann TA, Brechbiel MW.
Preparation and in vivo evaluation of a novel stabilized linker for (211)At labeling of protein.
Nucl. Med. Biol. 33: 469-80, 2006.
[Journal]
101)  Murad GJ, Walbridge S, Morrison PF, Garmestani K, Degen JW, Brechbiel MW, Oldfield EH, Lonser RR.
Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin.
Clin. Cancer Res. 12: 3145-51, 2006.
[Journal]
102)  Chong H, Garmestani K, Bryant LH, Milenic DE, Overstreet T, Birch N, Le T, Brady ED, Brechbiel MW.
Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging.
J Med Chem. 2055-62, 2006.
[Journal]
103)  Dadachova E, Patel MC, Toussi S, Apostolidis C, Morgenstern A, Brechbiel MW, Gorny MK, Zolla-Pazner S, Casadevall A, Goldstein H.
Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.
PLoS Med. 3: e427, 2006.
[Journal]
104)  Zhang M, Yao Z, Zhang Z, Garmestani K, Talanov VS, Plascjak PS, Yu S, Kim HS, Goldman CK, Paik CH, Brechbiel MW, Carrasquillo JA, Waldmann TA.
The Anti-CD25 Monoclonal Antibody 7G7/B6, Armed with the {alpha}-Emitter 211At, Provides Effective Radioimmunotherapy for a Murine Model of Leukemia.
Cancer Res. 66: 8227-32, 2006.
[Journal]
105)  Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW.
Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.
J. Med. Chem. 49: 4297-304, 2006.
[Journal]
106)  Yordanov AT, Mollov N, Lodder AL, Woller E, Cloninger M, Walbridge MD, Brechbiel MW.
A water-soluble triiodo amino acid and its dendrimer conjugate for computerized tomography (CT) imaging.
J Serb. Chem Soc. 70: 163-70, 2005.
[Journal]
107)  Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW.
Alpha-particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2.
Cancer Biother. Radiopharm. 20: 557-68, 2005.
[Journal]
108)  Boswell CA, Brechbiel MW.
Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you.
J. Nucl. Med. 46: 1946-7, 2005.
[Journal]
109)  Vearing C, Lee FT, Wimmer-Kleikamp S, Spirkoska V, To C, Stylianou C, Spanevello M, Brechbiel M, Boyd AW, Scott AM, Lackmann M.
Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.
Cancer Res. 65: 6745-54, 2005.
[Journal]
110)  Dear JW, Kobayashi H, Jo SK, Holly MK, Hu X, Yuen PS, Brechbiel MW, Star RA.
Dendrimer-enhanced MRI as a diagnostic and prognostic biomarker of sepsis-induced acute renal failure in aged mice.
Kidney Int. 67: 2159-67, 2005.
[Journal]
111)  Kobayashi H, Kawamoto S, Brechbiel MW, Bernardo M, Sato N, Waldmann TA, Tagaya Y, Choyke PL.
Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle.
Neoplasia. 7: 984-91, 2005.
[Journal]
112)  Panousis C, Rayzman VM, Johns TG, Renner C, Liu Z, Cartwright G, Lee FT, Wang D, Gan H, Cao D, Kypridis A, Smyth FE, Brechbiel MW, Burgess AW, Old LJ, Scott AM.
Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR.
Br J Cancer. 92: 1069-77, 2005.
[Journal]
113)  Lee FT, Mountain AJ, Kelly MP, Hall C, Rigopoulos A, Johns TG, Smyth FE, Brechbiel MW, Nice EC, Burgess AW, Scott AM.
Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Clin. Cancer Res. 11: 7080s-7086s, 2005.
[Journal]
114)  Qu CF, Songl YJ, Rizvi SM, Li Y, Smith R, Perkins AC, Morgenstern A, Brechbiel M, Allen BJ.
In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A.
Cancer Biol. Ther. 4: 848-53, 2005.
[Journal]
115)  Rogers BE, Roberson PL, Shen S, Khazaeli MB, Carpenter M, Yokoyama S, Brechbiel MW, LoBuglio AF, Buchsbaum DJ.
Intraperitoneal radioimmunotherapy with a humanized anti-TAG-72 (CC49) antibody with a deleted CH2 region.
Cancer Biother. Radiopharm. 20: 502-13, 2005.
[Journal]
116)  Regino CA, Torti SV, Ma R, Yap GP, Kreisel KA, Torti FM, Planalp RP, Brechbiel MW.
N-picolyl derivatives of Kemp's triamine as potential antitumor agents: a preliminary investigation.
Adv. Drug Deliv. Rev. 48: 7993-9, 2005.
[Journal]
117)  Kobayashi H, Brechbiel MW.
Nano-sized MRI contrast agents with dendrimer cores.
Adv Drug Deliv Rev. 57: 2271-86, 2005.
[Journal]
118)  Venditto VJ, Regino CA, Brechbiel MW.
PAMAM dendrimer based macromolecules as improved contrast agents.
Mol Pharm. 2: 302-11, 2005.
[Journal]
119)  Torti SV, Ma R, Venditto VJ, Torti FM, Planalp RP, Brechbiel MW.
Preliminary evaluation of the cytotoxicity of a series of tris-2-aminoethylamine (Tren) based hexadentate heterocyclic donor agents.
Bioorg. Med. Chem. 13: 5961-7, 2005.
[Journal]
120)  Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA.
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
J. Nucl. Med. 46: 1201-9, 2005.
[Journal]
121)  Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, Lin Y, Park L, Brechbiel MW, Pastan I, Paik CH, Carrasquillo JA.
Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein.
J Nucl Med. 46: 1201-9, 2005.
[Journal]
122)  Garmestani K, Milenic DE, Brady ED, Plascjak PS, Brechbiel MW.
Purification of cyclotron-produced 203Pb for labeling Herceptin.
Nucl Med Biol. 32: 301-5, 2005.
[Journal]
123)  Vallera DA, Brechbiel MW, Burns LJ, Panoskaltsis-Mortari A, Dusenbery KE, Clohisy DR, Vitetta ES.
Radioimmunotherapy of CD22-expressing Daudi tumors in nude mice with a 90Y-labeled anti-CD22 monoclonal antibody.
Clin. Cancer Res. 11: 7920-8, 2005.
[Journal]
124)  Turner J, Koumenis C, Kute TE, Planalp RP, Brechbiel MW, Beardsley D, Cody B, Brown KD, Torti FM, Torti SV.
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.
Blood. 106: 3191-9, 2005.
[Journal]
125)  Turner J, Koumenis C, Kute TE, Planalp RP, Brechbiel MW, Beardsley D, Cody B, Brown KD, Torti FM, Torti SV.
Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.
Blood. 106: 3191-9, 2005.
[Journal]
126)  Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Marks JD, Brechbiel MW, Weiner LM.
A Single Treatment of 90Y-CHX-A” C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice.
Cancer Res. 64: 6200-6206, 2004.
[Journal]
127)  Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM.
A single treatment of yttrium-90-labeled CHX-A.
Cancer Res. 64: 6200-6, 2004.
[Journal]
128)  Zhang M, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia.
Cancer Res. 64: 5825-9, 2004.
[Journal]
129)  Brady ED, Milenic DE, Brechbiel MW.
Antibody Guided Precision Therapy.
Disc. Med. 4: 213, 2004.
[Journal]
130)  Milenic DE, Brady ED, Brechbiel MW.
Antibody Targeted Radiation Cancer Therapy.
Nature Rev. Drug Disc. 3: 488-498, 2004.
[Journal]
131)  Milenic DE, Brady ED, Brechbiel MW.
Antibody Targeted Radiation Cancer Therapy.
Nature Rev. Drug Disc. 3: 488-498, 2004.
[Journal]
132)  Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, Mitchell JB, Brechbiel MW.
Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation.
Clin Cancer Res. 10: 7712-20, 2004.
[Journal]
133)  Yao Z, Zhang M, Garmestani K, Axworthy DB, Mallett RW, Fritzberg AR, Plascjak PS, Eckelman WC, Waldmann TA, Pastan I, Paik CH, Brechbiel MW.
Carrasquillo: Pretargeted alpha emitting radioimmunotherapy using 213Bi DOTA-biotin.
Clin. Cancer Res. 10: 3137-3146, 2004.
[Journal]
134)  Kobayashi H, Brechbiel MW.
Dendrimer-based nanosized MRI contrast agents.
Curr Pharm Biotech. 5: 539-49, 2004.
[Journal]
135)  Brady ED, Chong HS, Milenic DE, Brechbiel MW.
Development of a Spectroscopy Assay for Bifunctional Ligand-Protein Conjugates based on Copper.
Nucl. Med. Biol. 31: 795-802, 2004.
[Journal]
136)  Brady ED, Chong HS, Milenic DE, Brechbiel MW.
Development of a Spectroscopy Assay for Bifunctional Ligand-Protein Conjugates based on Copper.
Nucl. Med. Biol. 31: 795-802, 2004.
[Journal]
137)  Yao Z, Dai W, Perry J, Brechbiel MW, Sung C.
Effect of albumin fusion on the biodistribution of interleukin-2.
Cancer Immunol. Immunotherapy. 53: 404-410, 2004.
[Journal]
138)  Yao Z, Dai W, Perry J, Brechbiel MW, Sung C.
Effect of albumin fusion on the biodistribution of interleukin-2.
Cancer Immunol. Immunotherapy. 53: 404-410, 2004.
[Journal]
139)  Camphausen K, Sproull M, Tantama S, Venditto V, Sankineni S, Scott T, Brechbiel MW.
Evaluation of chelating agents as anti-angiogenic therapy through copper chelation.
Bioorg Med Chem. 12: 5133-40, 2004.
[Journal]
140)  Mamede M, Saga T, Ishimori T, Higashi T, Sato N, Kobayashi H, Brechbiel MW, Konishi J.
Hepatocyte targeting of 111In-labeled oligo-DNA with avidin or avidin-dendrimer complex.
J Control Release. 95: 133-41, 2004.
[Journal]
141)  Mamede M, Saga T, Ishimori T, Higashi T, Sato N, Kobayashi H, Brechbiel MW, Konishi J.
Hepatocyte-Targeting of 111In Labeled Oligo-DNA with Avidin or Avidin-Dendrimer Complex.
J. Control. Release. 95: 133-141, 2004.
[Journal]
142)  Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA.
Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity.
Cancer Res. 64: 1460-7, 2004.
[Journal]
143)  Mandler R, Kobayashi H, Hinson ER, Brechbiel MW, Waldmann TA.
Herceptin:geldanamycin immunoconjugates - pharmacokinetics, biodistribution, and enhanced anti-tumor activity.
Cancer Res. 64: 1460-1467, 2004.
[Journal]
144)  Kobayashi H, Kawamoto S, Sakai Y, Choyke PL, Star RA, Brechbiel MW, Sato N, Tagaya Y, Morris JC, Waldmann TA.
Lymphatic Drainage Imaging of Breast Cancer in Mice by Micro-Magnetic Resonance Lymphangiography using a Nano-size Paramagnetic Contrast Agent.
J. Natl. Cancer Inst. 96: 703-708, 2004.
[Journal]
145)  Kobayashi H, Kawamoto S, Sakai Y, Choyke PL, Star RA, Brechbiel MW, Sato N, Tagaya Y, Morris JC, Waldmann TA.
Lymphatic Drainage Imaging of Breast Cancer in Mice by Micro-Magnetic Resonance Lymphangiography using a Nano-size Paramagnetic Contrast Agent.
J. Natl. Cancer Inst. 96: 703-708, 2004.
[Journal]
146)  Ye N, Park G, Przyborowska AM, Sloan PE, Clifford T, Bauer CB, Broker GA, Rogers RD, Ma R, Torti SV, Brechbiel MW, Planalp RP.
Metal-binding Properties and Cytotoxicities of Tripodal Hexamine Chelators Prepared from cis,cis-1,3,5-Triaminocyclohexane.
Chem. Soc., Dalton Trans. 1304-1311, 2004.
[Journal]
147)  Ye N, Park G, Przyborowska AM, Sloan PE, Clifford T, Bauer CB, Broker GA, Rogers RD, Ma R, Torti SV, Brechbiel MW, Planalp RP.
Metal-binding Properties and Cytotoxicities of Tripodal Hexamine Chelators Prepared from cis,cis-1,3,5-Triaminocyclohexane.
J. Chem. Soc., Dalton Trans. 1304-1311, 2004.
[Journal]
148)  Kobayashi H, Kawamoto S, Brechbiel MW, Jo SK, Hu X, Yang T, Diwan BA, Waldmann TA, Schnermann J, Choyke PL, Star RA.
Micro-MRI methods to detect renal cysts in mice.
Kidney Int. 64: 1511-1516, 2004.
[Journal]
149)  Kobayashi H, Kawamoto S, Brechbiel MW, Jo SK, Hu X, Yang T, Diwan BA, Waldmann TA, Schnermann J, Choyke PL, Star RA.
Micro-MRI methods to detect renal cysts in mice.
Kidney Int. 65: -1516, 2004.
[Journal]
150)  Kobayashi H, Jo SK, Kawamoto S, Yasuda H, Hu X, Knopp MV, Brechbiel MW, Choyke PL, Star RA.
Polyamine Dendrimer-Based MRI Contrast Agents for the Functional Imaging to Diagnose the Acute Renal Failure.
Mag. Res. Imag. 20: 512-518, 2004.
[Journal]
151)  Talanov VS, Yordanov AT, Garmestani K, Milenic DE, Arora HC, Plascjak PS, Eckelman WC, Waldmann TA, Brechbiel MW.
Preparation and in vivo evaluation of novel linkers for 211At labeling of proteins.
Nucl Med Biol. 31: 1061-71, 2004.
[Journal]
152)  Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, Casadevall A, Pirofski L.
Radioimmunotherapy of experimental pneumococcal infection - a feasibility study.
Antimicrobial Agents Chemotherapy. 48: 1624-1629, 2004.
[Journal]
153)  Dadachova E, Burns T, Bryan RA, Apostolidis C, Brechbiel MW, Nosanchuk JD, Casadevall A, Pirofski L.
Radioimmunotherapy of experimental pneumococcal infection - a feasibility study.
Antimicrobial Agents Chemotherapy. 48: 1624-1629, 2004.
[Journal]
154)  Milenic D, Garmestani K, Dadachova E, Chappell L, Albert P, Hill D, Schlom J, Brechbiel M.
Radioimmunotherapy of Human Colon Carcinoma Xenografts using a 213Bi-Labeled Domain-Deleted Humanized Monoclonal Antibody.
Cancer Biotherapy Radiopharm. 19: 135-148, 2004.
[Journal]
155)  Milenic D, Garmestani K, Dadachova E, Chappell L, Albert P, Hill D, Schlom J, Brechbiel M.
Radioimmunotherapy of Human Colon Carcinoma Xenografts using a 213Bi-Labeled Domain-Deleted Humanized Monoclonal Antibody.
Cancer Biotherapy Radiopharm. 19: 135-148, 2004.
[Journal]
156)  Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Sandmaier BM.
Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose De-escalation Study.
Transplantation. 78: 352-359, 2004.
[Journal]
157)  Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Sandmaier BM.
Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.
Transplantation. 78: 352-9, 2004.
[Journal]
158)  Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, Vitetta ES, Kersey JH.
Radiotherapeutic studies of the tumorogenic CD19+ Daudi Cell line Yttrium-90-labeled anti-CD19 antibody in nude mice.
Cancer Biotherapy Radiopharm. 19: 11-24, 2004.
[Journal]
159)  Zhao R, Planalp RP, Ma R, Greene BT, Jones BT, Brechbiel MW, Torti FM, Torti SV.
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
Biochem. Pharmacol. 67: 1677-1688, 2004.
[Journal]
160)  Zhao R, Planalp RP, Ma R, Greene BT, Jones BT, Brechbiel MW, Torti FM, Torti SV.
Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
Pharmacol. 67: 1677-1688, 2004.
[Journal]
161)  Chong HS, Torti SV, Ma R, Torti FM, Brechbiel MW.
Synthesis and potent antitumor activities of novel 1,3,5-cis,cis-triaminocyclohexane N-pyridyl derivatives.
J Med Chem. 47: 5230-4, 2004.
[Journal]
162)  Wesley JN, McGee EC, Garmestani K, Brechbiel MW, Yordanov AT, Wu C, Gansow OA, Eckelman WC, Bacher JD, Flynn M, Goldman CK, Maclin M, Schwartz UP, Jackson-White T, Phillip CM, Decker J, Waldmann TA.
Systemic radioimmunotherapy with a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclide 212Bi or 211At.
Nucl. Med. Biol. 31: 357-364, 2004.
[Journal]
163)  Wesley JN, McGee EC, Garmestani K, Brechbiel MW, Yordanov AT, Wu C, Gansow OA, Eckelman WC, Bacher JD, Flynn M, Goldman CK, Maclin M, Schwartz UP, Jackson-White T, Phillip CM, Decker J, Waldmann TA.
Systemic radioimmunotherapy with a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclide 212Bi or 211At.
Nucl. Med. Biol. 31: 357-364, 2004.
[Journal]
164)  Milenic DE, Garmestani K, Brady ED, Albert PS, Ma D, Abdulla A, Brechbiel MW.
Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.
Clin Cancer Res. 10: 7834-41, 2004.
[Journal]
165)  Milenic D, Brechbiel MW.
Targeting of Radio-isotopes for Cancer Therapy.
Cancer Biol. Therapy. 3: 361-370, 2004.
[Journal]
166)  Milenic D, Brechbiel MW.
Targeting of Radio-isotopes for Cancer Therapy.
Cancer Biol. Therapy. 3: 361-370, 2004.
[Journal]
167)  Smart DK, Ortiz KL, Mattson D, Bradbury CM, Bisht KS, Sieck LK, Brechbiel MW, Gius D.
Thioredoxin reductase as a potential molecular target for anticancer agents that induce oxidative stress.
Cancer Res. 64: 6716-24, 2004.
[Journal]
168)  Michel RB, Brechbiel MW, Mattes MJ.
A Comparison of Radionuclides Conjugated to Antibodies for Single-Cell Kill.
J. Nucl. Med. 44: 632-640, 2003.
[Journal]
169)  Chong HS, Brechbiel MW.
A Short and Efficient Synthesis of Mono-Substituted 1,4,7-Triazacyclononanes.
Syn. Commun. 33: 1147-1154, 2003.
[Journal]
170)  Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Brechbiel MW, Choyke PL.
Activated Clearance of a Macromolecular MR Contrast Agent from the Blood Pool to the Liver Using an Avidin-Biotin System.
Bioconjugate Chem. 14: 1044-1047, 2003.
[Journal]
171)  Sproull M, Brechbiel M, Camphausen K.
Anti-angiogenic Therapy Through Copper Chelation.
Expert Opin. Ther. Targets. 7: 405-409, 2003.
[Journal]
172)  Wang SJ, Brechbiel M, Wiener EC.
Characteristics of a New MRI Contrast Agent Prepared from PolyPropyleneImine Dendrimers, Generation 2.
Invest. Radiol. 38: 662-668, 2003.
[Journal]
173)  Kobayashi H, Kawamoto S, Choyke PL, Sato N, Knopp MV, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW.
Comparison of Dendrimer-Based Macromolecular Contrast Agents for Dynamic Micro-Magnetic Resonance Lymphangiography.
Mag. Res. Med. 50: 758-766, 2003.
[Journal]
174)  Camphausen K, Sproull M, Tanawa S, Sankineni S, Scott T, Ménard C, Coleman CN, Brechbiel MW.
Evaluation of Copper Chelation Agents as Anti-Angiogenic Therapy.
Bioorg. Med. Chem. 11: 4287-4291, 2003.
[Journal]
175)  Michel RB, Rosario AV, Brechbiel MW, Jackson TJ, Goldenberg DM, Mattes MJ.
Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74.
Nucl. Med. Biol. 30: 715-723, 2003.
[Journal]
176)  Michel RB, Rosario AV, Brechbiel MW, Jackson TJ, Goldenberg DM, Mattes MJ.
Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74.
Nucl. Med. Biol. 30: 715-723, 2003.
[Journal]
177)  Kobayashi H, Brechbiel MW.
Gadolinium-based Macromolecular MRI Contrast Agents.
Molecular Imaging. 2: 1-11, 2003.
[Journal]
178)  Yordanov AT, Kobayashi H, English SJ, Reijnders K, Milenic D, Krishna MC, Mitchell JB, Brechbiel MW.
Gadolinium-Labeled Dendrimers as Biometric Nanoprobes to Detect Vascular Permeability.
J. Mat. Chem. 13: 1523-1525., 2003.
[Journal]
179)  Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Coleman CN, Neckers LM, Gius D.
Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin Potentiate the In Vitro and In Vivo Radiation Response of Cervical Tumor Cells via HSP90-Mediated Intracellular Signaling and Cytotoxicity.
Cancer Res. 63: 8984-8995, 2003.
[Journal]
180)  Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, Ortiz KL, Sieck LK, Isaacs JS, Brechbiel MW, Mitchell JB, Coleman CN, Neckers LM, Gius D.
Geldanamycin and 17-Allylamino-17-Demethoxygeldanamycin Potentiate the In Vitro and In Vivo Radiation Response of Cervical Tumor Cells via HSP90-Mediated Intracellular Signaling and Cytotoxicity.
Cancer Res. 63: 8984-8995, 2003.
[Journal]
181)  Nguyen TT, Pannu YS, Sung C, Dedrick RL, Walbridge S, Brechbiel MW, Garmestani K, Beitzel M, Yordanov AT, Oldfield EH.
Imaging Convective Distribution of Macromolecules in the Primate Brain using CT and MRI.
J. Neurosurgery. 98: 584-590, 2003.
[Journal]
182)  Blend MJ, Stastny JJ, Swanson SM, Brechbiel MW.
Labeling anti-HER2/neu Monoclonal Antibodies with 111In and 90Y using a Bifunctional DTPA Chelating Agent.
Cancer Biotherapy Radiopharm. 18: 355, 2003.
[Journal]
183)  Kobayashi H, Kawamoto S, Jo SK, Bryant HL, Brechbiel MW, Star RA.
Macromolecular MRI Contrast Agents with Small Dendrimers: Pharmacokinetic Differences between Sizes and Cores.
Bioconjugate Chem14. 14: 388-394, 2003.
[Journal]
184)  Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Tagaya Y, Brechbiel MW.
Micro-Magnetic Resonance Lymphoangiography of Mice using a novel Dendrimer-based MRI Contrast Agents.
Cancer Res. 63: 271-276, 2003.
[Journal]
185)  Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Skubitz KM, Jaszcz WB, Ramsay NK, Panoskaltsis-Mortari A, Kuroki DW, Wagner JE, Kersey JH.
Preclinical studies targeting normal and leukemic hematopoietic cells with Yttrium-90-labeled anti-CD45 antibody in vitro and in vivo in nude mice.
Cancer Biotherapy Radiopharm. 18: 133-145, 2003.
[Journal]
186)  Zhang M, Zhang Z, Garmestani K, Schultz J, Axworthy DB, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Pretargetâ radioimmunotherapy provides effective treatment for lymphoma and leukemia xenografts.
Proc. Natl. Acad. Sci., USA. 100,: 1891-1895, 2003.
[Journal]
187)  Mamede M, Saga T, Kobayashi H, Ishimori T, Higashi T, Sato N, Brechbiel MW, Konishi J.
Radiolabeling of Avidin with Very High Specific Activity for Internal Radiation Therapy of Intraperitoneally Disseminated Tumors.
Clin. Cancer Res. 9: 3756-3762, 2003.
[Journal]
188)  Bethge WA, Wilbur DS, Storb R, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Sandmaier BM.
Selective T-cell ablation with bismuth-213 labeled anti-TCRab as nonmyeloablative conditioning for allogeneic canine marrow transplantation.
Blood. 101: 5068-5075, 2003.
[Journal]
189)  Park G, Przyborowska AM, Ye N, Tsoupas NM, Bauer CB, Broker GA, Rogers RD, Brechbiel MW, Planalp RP.
Steric effects caused by N-alkylation of the tripodal chelator N, N’, N’’-tris(2-pyridylmethyl)-cis,cis-1,3,5-triaminocyclohexane (tachpyr): structural and electronic properties of the Mn(II), Co(II), Ni(II), Cu(II) and Zn(II) complexes.
J. Chem. Soc., Dalton Trans. 318-324, 2003.
[Journal]
190)  Chappell LL, Ma D, Milenic DE, Garmestani K, Venditto V, Beitzel MP, Brechbiel MW.
Synthesis and Evaluation of Novel Bifunctional Chelating Agents Based on 1,4,7,10-Tetraazacyclododecane-N,N’,N’’,N’’’-Tetraacetic Acid for Radiolabeling Proteins.
Nucl. Med. Biol. 30: 581-595, 2003.
[Journal]
191)  Mitchell P, Lee FT, Hall C, Rigopoulos A, Smyth FE, Hekman AM, Powles R, Brechbiel MW, Scott AM.
Targeting Primary Human Ph+ B-cell Precursor Leukemia Engrafted SCID Mice Using Radiolabelled Anti-CD19 Monoclonal Antibodies.
J. Nucl. Med. 44: 1105-1112, 2003.
[Journal]
192)  Garmestani K, Milenic DE, Plascjak PS, Brechbiel MW.
A New and Convenient Method for Purification of 86Y using a Sr(II) Selective Resin and Comparison of Biodistribution of 86Y and 111In labeled HerceptinTM Nucl.
Nucl. Med. Biol. 29: 599-606, 2002.
[Journal]
193)  Mandler R, Kobayashi H, Davis MY, Waldmann TA, Brechbiel MW.
A Second-Generation Geldanamycin-Herceptinä Immunoconjugate Yields Improved in vitro and in vivo Efficacy.
Bioconjugate Chem. 13: 786-791, 2002.
[Journal]
194)  Kennel SJ, Brechbiel MW, Milenic DE, Schlom J, Mirzadeh S.
Actinium-225 conjugates of MAb CC49 and Humanized CH2CC49: Therapy of LS174T tumors in nude mice.
Cancer Biotherapy and Radiopharm. 17: 219-231, 2002.
[Journal]
195)  Greene BT, Thorburn J, Thorburn A, Planalp RP, Brechbiel MW, Torti FM, Torti SV.
Activation of Caspase Pathways during Iron Chelator-Mediated Apoptosis.
J. Biol. Chem. 277: 25568-25575, 2002.
[Journal]
196)  Yordanov AT, Yamada K, Krishna MC, Russo A, Yoo J, English S, Mitchell JB, Brechbiel MW.
Acyl-Protected Hydroxylamines as Spin Label Generators for EPR Brain Imaging.
J. Med. Chem. 45: 2283-2288, 2002.
[Journal]
197)  Yordanov AT, Lodder A, Woller E, Cloninger M, Patronas N, Milenic D, Brechbiel MW.
First Water-Soluble Dendrimer-Based Iodinated Nanoparticles for Computed Tomography (CT) Imaging.
NanoLetters. 2: 595-599, 2002.
[Journal]
198)  Kobayashi H, Shirakawa K, Heike Y, Kawamoto S, Brechbiel MW, Kasumi F, Iwanaga T, Konishi F, Terada M, Wakasugi H.
Hemodynamics in Vasculogenic Mimicry and Angiogenesis of Inflammatory Breast Cancer Xenograft.
Cancer Res. 62: 560-566, 2002.
[Journal]
199)  Aref M, Brechbiel M, Wiener EC.
Identifying Tumor Permeability Heterogeneity with MRI Contrast Agents.
Invest. Rad. 37: 178-192, 2002.
[Journal]
200)  Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, Schlom J, Brechbiel MW.
In Vivo Comparison of Macrocyclic and Acyclic Ligands for Radiolabeling of Monoclonal Antibodies with 177Lu for Radioimmunotherapeutic Applications.
Nucl. Med. Biol. 29: 431-442, 2002.
[Journal]
201)  Samuni AM, Krishna MC, DeGraff W, Russo A, Planalp RP, Brechbiel MW, Mitchell JB.
Mechanisms Underlying the Cytotoxic Effects of Tachpyr - a Novel Metal Chelator.
Biochem Biophys. Acta. 1571: 211-218, 2002.
[Journal]
202)  Ma D, Lu F, Overstreet T, Milenic DE, Brechbiel MW.
Novel Chelating Agents for Potential Clinical Applications of Copper.
Nucl. Med. Biol. 29: 91-105, 2002.
[Journal]
203)  Planalp RP, Przyborowska AM, Park G, Ye N, Lu FH, Rogers RD, Broker GA, Torti SV, Brechbiel MW.
Novel cytotoxic chelators that bind iron(II) selectively over zinc(II) under aqueous aerobic conditions.
Biochem. Soc. Trans. 30: 758-762, 2002.
[Journal]
204)  Chong HS, Garmestani K, Bryant LH, Brechbiel MW.
Potential Contrast Enhancement Agents For Magnetic Resonance Imaging (MRI).
J. Org. Chem. 29: 91-105, 2002.
[Journal]
205)  Zhang M, Yao Z, Garmestani K, Axworthy D, Zhang Z, Mallett B, Theodore L, Goldman CK, Brechbiel MW, Carrasquillo JA, Waldmann TA.
Pretargeting radioimmunotherapy of a murine model of adult T cell leukemia (ATL) with the alpha emitting radionuclide, Bi-213.
Blood. 100: 208-216, 2002.
[Journal]
206)  Ma D, Barendswaard E, McDevitt MR, Lai L, Curcio MJ, Pellegrini V, Brechbiel MW, Scheinberg DA.
Radioimmunotherapy for B-cell Malignancies using 90Y Labeled anti-CD19 Monoclonal Antibody.
Leukemia. 16: 60-66, 2002.
[Journal]
207)  Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA.
Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and 90Y-DOTA-biotin.
Cancer Res. 62: 5755-5760, 2002.
[Journal]
208)  Brechbiel MW, Milenic DE, Garmestani K, Abdulla A, Overstreet T, Flynn J.
Radioimmunotherapy of Intraperitoneal Disseminated Disease: Preliminary Evaluation of Herceptin as a Radioimmunoconjugate. In "Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 6".
(Ed. M. Nicolini and U. Mazzi), SGE Editoriali, Padova, Italy. 587-588, 2002.
[Journal]
209)  Kobayashi H, Shirakawa K, Kawamoto S, Saga T, Sato N, Hiraga A, Watanabe I, Heike Y, Togashi K, Konishi J, Brechbiel MW, Wakasugi H.
Rapid Accumulation and Internalization of Radiolabeled HerceptinTM in a Inflammatory Breast Cancer Xenograft with Vasculogenic Mimicry Predicted by the Contrast-Enhanced Dynamic MRI with a Macromolecular Contrast Agent G6-(1B4M-Gd)256.
Cancer Res. 62: 860-866, 2002.
[Journal]
210)  Kobayashi H, Kawamoto S, Jo S, Sato N, Saga T, Hiraga A, Togashi K, Konishi , Brechbiel M, Star R.
Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent.
Kidney Int. 61: 1980-85, 2002.
[Journal]
211)  Chong H, Ganguly B, Broker G, Rogers R, Brechbiel MW.
Stereoselective and Regioselective Synthesis of Azepane and Azepine Derivatives via Piperidine Ring Expansion.
J. Chem. Soc., Perkin Trans. 1,. 18: 2080-2086, 2002.
[Journal]
212)  Lonser RR, Walbridge S, Garmestani K, Butman JA, Walters HA, Vortmeyer AO, Brechbiel MW, Oldfield EA.
Successful and safe perfusion of the primate brainstem with a macromolecule: in vivo magnetic resonance imaging of macromolecular distribution during infusion.
J. Neurosurgery. 30: 758-762, 2002.
[Journal]
213)  Chong HS, Garmestani K, Ma D, Milenic D, Overstreet T, Brechbiel MW.
Synthesis and Biological Evaluation of Novel Macrocyclic Ligands With Pendant Donor Groups As Potential Yttrium Chelators For Radioimmunotherapy With Improved Complex Formation Kinetics.
J. Med. Chem. 45: 3458-3464, 2002.
[Journal]
214)  Chong HS, Torti FM, Torti SV, Brechbiel MW.
Synthesis of 1,3,5-Cis,Cis-Triaminocyclohexane N-Pyridyl Derivatives As Potential Anti-Tumor Agents.
J. Org. Chem. 67: 8072-8078, 2002.
[Journal]
215)  Chong HS, Torti FM, Torti SV, Brechbiel MW.
Synthesis of 1,3,5-Cis,Cis-Triaminocyclohexane N-Pyridyl Derivatives As Potential Anti-Tumor Agents.
J. Org. Chem. 67: 8072-8078, 2002.
[Journal]
216)  Jurcic JG, Sgouros G, McDevitt MR, Finn RD, Ballangrud AM, Klaus AKA, Divgi CR, Humm JL, Brechbiel MW, Molinet R, Larson SM, Scheinberg DA.
Targeted  Particle Immunotherapy in Humans.
Blood. 100: 1233-1239, 2002.
[Journal]
217)  Eckelman WC, Frank JA, Brechbiel M.
Theory and Practice of Imaging Saturable Binding Sites.
Invest. Radiol. 37: 101-106, 2002.
[Journal]
218)  Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Nilsson R, Sandberg BE, Brechbiel M.
Trifunctional Conjugation Reagents. Reagents that contain a Biotin and a Radiometal Chelation Moiety for Application to Extracorporeal Affinity-Adsorption of Radiolabeled Antibodies.
Bioconjugate Chem. 13: 211-281, 2002.
[Journal]
219)  Sandmaier BM, Bethge WA, Wilbur DS, Hamlin DK, Santos EB, Brechbiel MW, Fisher DR, Storb R.
Use of a 213Bismuth Labeled Anti-CD45 Radioimmunoconjugate to Condition Dogs for Non-myeloablative Canine Marrow Grafts.
Blood. 100: 318-326, 2002.
[Journal]
220)  Kennel SJ, Mirzadeh S, Eckelman WC, Waldmann TA, Garmastani K, Yordanov AT, Stabin M, Brechbiel MW.
Vascular Targeted Radioimmunotherapy with the -emitter 211At.
Radiation Res. 157: 633-641, 2002.
[Journal]
221)  Kobayashi H, Sato N, Kawamoto S, Saga T, Hiraga A, Haque TL, Ishimora T, Konishi J, Togashi K, Brechbiel MW.
3D MR Angiography of Intratumoral Vasculature using a Novel Macromolecular MR Contrast Agent. Mag.
Mag. Res. Med. 46: 579-585, 2001.
[Journal]
222)  Kobayashi H, Sato N, Hiraga A, Saga T, Nakamoto Y, Ueda H, Konishi J, Togashi K, Brechbiel MW.
3D-micro-MR Angiography using Macromolecular MR Contrast Agents with Reference to Their Pharmacokinetic Properties.
Mag. Res. Med. 45: 454-460, 2001.
[Journal]
223)  Luo H, Rogers RD, Brechbiel MW.
A Convenient and Selective Route to trans-Difunctionalized Macrocyclic Hexadentate N4O2 Ligand.
Can. J. Chem. 79: 1105-1109, 2001.
[Journal]
224)  Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Mamede MH, Konishi J, Togashi K, Brechbiel MW.
A Novel Liver Macromolecular MR Contrast Agent with Polypropyleneimine Tetrahexacontaamine Dendrimer Core: Comparison to the Vascular MR Contrast Agent with Polyamidoamine Dendrimer Core.
Mag. Res. Med. 46: 795-802, 2001.
[Journal]
225)  Kobayashi H, Kawamoto S, Saga T, Sato N, Ishimori T, Konishi J, Ono K, Togashi K, Brechbiel MW.
Avidin-dendrimer-(1B4M-Gd)254: a tumor-targeting therapeutic agent for gadolinium neutron capture therapy of intraperitoneal disseminated tumor which can be monitored by MRI.
Bioconjugate Chem. 12: 587-593, 2001.
[Journal]
226)  Tahtis K, Lee FT, Smyth F, Power BE, Renner C, Brechbiel MW, Old LJ, Hudson PJ, Scott AM.
Biodistribution Properties of 111In-CHX-A=>-DTPA Humanised 3S193 (hu3S193) Diabody and F(ab=)2 Constructs in a Breast Carcinoma Xenograft Model.
Clin. Cancer Res. 7: 1061-1072, 2001.
[Journal]
227)  Kobayashi H, Sato N, Kawamoto S, Saga T, Hiraga A, Haque TL, Ishimori T, Konishi J, Togashi K, Brechbiel MW.
Comparison of the Macromolecular MR Contrast Agents with Ethylenediamine-core versus Ammonia-core Generation-6 Polyamidoamine Dendrimer.
Bioconjugate Chem. 12: 100-107, 2001.
[Journal]
228)  Park G, Shao J, Lu FH, Rogers RD, Chasteen ND, Brechbiel MW, Planalp RP.
Copper(II) Complexes of Novel N-Alkylated Derivatives of cis,cis-1,3,5-Triaminocyclohexane: I. Preparation and Structure.
Inorg. Chem. 40: 4167-4175, 2001.
[Journal]
229)  Deal KA, Park G, Shao J, Lu FH, Chasteen ND, Planalp RPBRECHBIEL.
Copper(II) Complexes of Novel N-Alkylated Derivatives of cis,cis-1,3,5-triaminocyclohexane: II. Metal-Promoted Phosphate Diester Hydrolysis.
Inorg. Chem. 40: 4176-4182, 2001.
[Journal]
230)  Park G, Dadachova E, Przyborowska A, Lai S, Broker G, Rogers RD, Planalp RP, Brechbiel MW.
Correlation of Structure and Serum Stability of Novel cis,cis-1,3,5-triaminocyclohexane Ligand Based Cu(II) Complexes as Potential Radiopharmaceuticals.
Polyhedron. 66: 7745-7750, 2001.
[Journal]
231)  Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Konishi J, Togashi K, Brechbiel MW.
Dedicated Intravascular MR Contrast Agents with High Generation of Polyamidoamine Dendrimer Core: Reference to Pharmacokinetic Properties of Dendrimer-based MR Contrast Agents.
J. Mag. Res. Imag. 14: 703-713, 2001.
[Journal]
232)  Kobayashi H, Saga T, Kawamoto S, Sato N, Hiraga A, Ishimori T, Mamede MH, Konishi J, Togashi K, Brechbiel MW.
Dynamic Micro-MRI of Liver Micrometastasis with a Novel Liver Macromolecular MR Contrast Agent DAB-Am64-(1B4M-Gd)64.
Cancer Res. 61: 4966-4970, 2001.
[Journal]
233)  Dadachova E, Park C, Eberly N, Paik CH, Brechbiel MW.
In vitro and in vivo characterization of 67Ga3+ complexes with cis,cis-1,3,5-triamino-cyclohexane- N,N=,N==-triacetic acid derivatives.
Nucl. Med. Biol. 28: 695-701, 2001.
[Journal]
234)  Milenic DE, Roselli M, Mirzadeh S, Pippin CG, Gansow OA, Colcher D, Brechbiel MW, Schlom J.
In Vivo Evaluation of Bismuth-Labeled Monoclonal Antibody Comparing DTPA-Derived Bifunctional Chelates.
Cancer Biother. Radiopharm. 16: 133-146, 2001.
[Journal]
235)  Samuni AM, Afeworki M, Stein W, Yordanov AT, DeGraff W, Krishna MC, Mitchell JB, Brechbiel MW.
Multifunctional antioxidant activity of HBED iron chelator.
Free Radical Biol. Med. 30: 170-177, 2001.
[Journal]
236)  Kobayashi H, Sato N, Hiraga A, Saga T, Kawamoto S, Ishimora T, Konishi J, Togashi K, Brechbiel MW.
Novel Intravascular Macromolecular MR Contrast Agents with Generation-4 Polyamidoamine Dendrimer Core: Accelerated Renal Excretion with Co-Injection of Lysine.
Mag. Res. Med. 46: 457-464, 2001.
[Journal]
237)  Zhao R, Planalp RP, Ma R, Greene BT, Jones BT, Brechbiel MW, Torti FM, Torti SV.
p53-Independent Apoptosis Mediated by Tachpyridine, a Potential Anti-Cancer Agent and Iron Chelator.
Carcinogenesis. 22: 845-856, 2001.
[Journal]
238)  Lovqvist A, Humm JL, Sheikh A, Koriorowski J, Ruan S, Pentlow K, Jungbluth A, Welt S, Lee FT, Brechbiel MW, Larson SM.
PET Imaging of 86Y-Labeled anti-Lewisy Antibodies in a Nude Mouse Model; Comparison Between 86Y and 111In Radiolabels.
J. Nucl. Med. 42: 1281-1287, 2001.
[Journal]
239)  Sato N, Kobayashi H, Hiraga A, Saga T, Togashi K, Konishi J, Brechbiel MW.
Pharmacokinetics and enhancement of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores.
Mag. Res. Med. 46: 1169-1173, 2001.
[Journal]
240)  Kobayashi H, Kawamoto S, Saga T, Sato N, Hiraga A, Ishimori T, Konishi J, Togashi K, Brechbiel MW.
Positive Effects of Polyethylene Glycol Conjugation to Generation-4 Polyamidoamine Dendrimers as Macromolecular MR Contrast Agents.
Mag. Res. Med. 46: 781-788, 2001.
[Journal]
241)  Yordanov AT, Garmestani K, Zhang M, Zhang Z, Yao Z, Phillips KE, Herring B, Horak E, Beitzel MP, Schwarz UP, Gansow OA, Plascjak PS, Eckelman WC, Waldmann TA, Brechbiel MW.
Preparation and In Vivo Evaluation of Linkers for 211At Labeling of Humanized Anti-Tac.
Nucl. Med. Biol. 28: 854-856, 2001.
[Journal]
242)  Lee FT, Rigopoulos A, Hall C, Liu Z, Brechbiel M, Gansow O, Hanai N, Nice E, Catimel B, Burgess A, Welt S, Ritter G, Old LJ, Scott AM.
Specific Localization, Gamma Camera Imaging and Intracellular Trafficking of Radiolableled Chimeric Anti-GD3 Ganglioside Monoclonal Antibody KM871 in SK-MEL-28 Melanoma Xenografts.
Cancer Res. 16: 4474-4482, 2001.
[Journal]
243)  Scott AM, Lee FT, Hopkins W, Cebon JS, Wheatley JM, Liu Z, Smyth FE, Murone C, Sturrock S, MacGregor D, Hanai N, Inoue K, Yamasaki M, Brechbiel MW, Davis ID, Murphy R, Hannah A, Lim-Joon M, Chan T, Chong G, Ritter G, Hoffman EW, Burgess AW, Old LJ.
Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial.
J. Clin. Oncol. 19: 3976-3987, 2001.
[Journal]
244)  Yordanov AT, Yamada Ki Ken-ichi, Krishna MC, Mitchell JB, Woller E, Cloninger M, Brechbiel MW.
Spin-Labeled Dendrimers in EPR Imaging with Low Molecular Weight Nitroxides.
Angewante Chemie, Int. Ed. Eng. 40: 2690-2692, 2001.
[Journal]
245)  Luo H, Eberly N, Rogers RD, Brechbiel MW.
Synthesis and Characterization of Metal Complexes Derived from H3tachta, cis,cis-1,3,5-triaminocyclohexane-N,N=,N=>-triacetic Acid.
Inorg. Chem. 40: 493-498, 2001.
[Journal]
246)  Garmestani K, Yao Z, Zhang M, Wong K, Park CW, Pastan I, Carrasquillo JA, Brechbiel MW.
Synthesis and Evaluation of a Macrocyclic Bifunctional Chelating Agent for use with Bismuth Radionuclides.
Nucl. Med. Biol. 28: 409-418, 2001.
[Journal]
247)  Renner C, Stehle I, Lee FT, Hall C, Catimel B, Nice EC, Mountain A, Rigopoulos A, Brechbiel MW, Pfreundschuh M, Scott AM.
Targeting Properties of an anti-CD16/anti-CD30 Bispecific Antibody in an in-vivo System.
Cancer Immunol. Immunotherap. 50: 102-108, 2001.
[Journal]
248)  Hassfjell S, Brechbiel MW.
The Development of the -Particle Emitting Radionuclides 212Bi and 213Bi for Therapeutic Applications.
Chem. Rev. 50: 102-108, 2001.
[Journal]
249)  Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, Fujibayashi Y, Konishi J, Brechbiel MW.
Tumor Targeting and Imaging of Intraperitoneal Tumors using Antisense Oligo-DNA Complexed with Dendrimers and/or Avidin in Mice.
Clin. Cancer Res. 7: 3606-3612, 2001.
[Journal]
250)  Kobayashi H, Sato N, Hiraga A, Saga T, Nakamoto Y, Ueda H, Konishi J, Togashi K, Brechbiel MW.
3D-micro-MR Angiography using Macromolecular MR Contrast Agents with Reference to Their Pharmacokinetic Properties.
Mag. Res. 45: 454-460, 2000.
[Journal]
251)  McDevitt MR, Barenswaard E, Ma D, Curcio MJ, Lai L, Sgouros G, Ballangrud AAM, Yang WH, Finn RD, Geerlings Jr MW, Brechbiel MW, Bander NH, Scheinberg DA.
An Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostates Cancer.
Cancer Res. 60: 6095-6100, 2000.
[Journal]
252)  Brechbiel MW, Waldmann TA.
Anti-HER2 Radioimmunotherapy.
Breast Disease. 11: 125-132, 2000.
[Journal]
253)  Brechbiel MW, Waldmann TA.
Anti-HER2 radioimmunotherapy.
Breast disease. 11: 125-32, 2000.
[Journal]
254)  Khosraviani M, Blake RC, Pavlov AR, Lorbach SC, Yu H, Delehanty JB, Brechbiel MW, Blake DA.
Binding Properties of a Monoclonal Antibody Directed toward Lead-Chelate Complexes.
Bioconjugate Chem. 11: 267-277, 2000.
[Journal]
255)  Chappell LL, Dadachova E, Milenic DE, Garmestani K, Wu C, Brechbiel MW.
Characterization, and Evaluation of a Novel Bifunctional Chelating Agent for the Lead Isotopes 203Pb and 212Pb.
Nucl. Med. Bio. 27: 93-100, 2000.
[Journal]
256)  Adams GP, Shaller CC, Chappell LL, Wu C, Horak EM, Simmons HH, Marks J, Weiner LM, Brechbiel MW.
Delivery of the Alpha-Emitting Radioisotope Bi-213 to Tumors via Single-Chain and Diabody Molecules.
Nucl. Med. Biol. 27: 339-346, 2000.
[Journal]
257)  Park G, Ye N, Roger RD, Brechbiel MW, Planalp RP.
Dicationic Metal Complexes ([MIIL][ClO4]2, M = Zn, Cd, and Hg) of N,N=,N=>-tris(2-methylenepyridyl)-cis-1,3,5-triaminocyclohexane: Preparation, Characterization, and Structures.
Polyhedron. 19: 1155-1161, 2000.
[Journal]
258)  Kennel SJ, Chappell LL, Dadachova K, Brechbiel MW, Lankford TK, Davis IA, Stabin M, Mirzadeh S.
Evaluation of 225Ac for Vascular Targeted Radioimmunotherapy of Lung Tumors.
Cancer Biother. Radiopharm. 15: 235-244, 2000.
[Journal]
259)  Bryant LH, Yordanov AT, Linnoila JJ, Brechbiel MW, Frank JA.
First Noncovalent Calix[4]arene-Gd-Albumin Complex.
Angewante Chemie, Int. Ed. Eng. 39: 1641-1643, 2000.
[Journal]
260)  Pai-Scherf LH, Carrasquillo JA, Paik C, Gansow O, Whatley M, Pearson D, Webber K, Hamilton M, Allegra C, Brechbiel M, Willingham MC, Pastan I.
Imaging and Phase I Study of 111In and 90Y labeled anti-LewisY Monoclonal Antibody B3.
Clin. Cancer Res. 6: 1720-1730, 2000.
[Journal]
261)  Mandler R, Wu C, Sausville EA, Roettinger AJ, Newman DJ, Ho DK, King CR, Yang D, Lippman ME, Landolfi NF, Dadachova E, Brechbiel MW, Waldmann TA.
Immunoconjugates of Geldanamycin and Anti-HER2 Monoclonal Antibodies: Antiproliferative Activity on Human Breast Carcinoma Cell Lines.
J. Natl. Cancer Inst. 92: 1573-1581, 2000.
[Journal]
262)  Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM.
In Vivo Biodistribution of a Humanized Anti-LewisY Monoclonal Antibody (hu3S193) in MCF-7 Xenografted BALB/c Nude Mice.
Cancer Res. 60: 4804-4811, 2000.
[Journal]
263)  Kennel SJ, Mirzadeh S, Hurst GB, Foote LJ, Lankford TK, Glowienka KA, Chappell LL, Kelso JR, Davern SM, Safavy A, Brechbiel MW.
Labeling and Distribution of Linear Peptides Identified using In Vivo Phage Display Selection for Tumors.
Nucl. Med. Biol. 27: 815-825, 2000.
[Journal]
264)  Planalp RP, Przyborowska AM, Park G, Ye N, Lu FH, Rogers RD, Broker GA, Torti SV, Brechbiel MW.
Novel cytotoxic chelators that bind iron(II) selectively over zinc(II) under aqueous aerobic conditions.
Biochem. Soc. Trans. 30: 758-762, 2000.
[Journal]
265)  Kobayashi H, Kao CH, Kreitman RJ, Kim MH, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA.
Pharmacokinetics of 111In- and 125I-labeled anti-Tac single-chain Fv recombinant immunotoxin.
J. Nucl. Med. 41: 755-762, 2000.
[Journal]
266)  Govindam SV, Goldenberg DM, Elsamra SE, Griffiths GL, Ong GL, Brechbiel MW, Burton J, Sgouros G, Mattes JM.
Radionuclides Linked to Anti-CD74 as Toxic Agents for B-Cell Lymphoma: Comparison of Auger Electron Emitters with -Particle Emitters.
J. Nucl. Med. 41: 2089-2097, 2000.
[Journal]
267)  Mandler R, Dadachova E, Brechbiel JK, Brechbiel MW.
Synthesis and Evaluation of Anti-Proliferative Activity of a Geldanamycin-HerceptinTM Immunoconjugate.
Bioorg. Med. Chem. Lett. 10: 1025-1028, 2000.
[Journal]
268)  Chappell LL, Deal KA, Dadachova E, Brechbiel MW.
Synthesis, Conjugation and Radiolabeling of a Novel Bifunctional Chelating agent for 225Ac Radioimmunotherapy Applications.
Bioconjugate. Chem. 11: 510-519, 2000.
[Journal]
269)  Konda SD, Aref M, Brechbiel MW, Wiener EC.
The Development of a Tumor Targeting Magnetic Resonance Contrast Agent utilizing the High Affinity Folate Receptor.
Invest. Radio. 35: 50-57, 2000.
[Journal]
270)  Kobayashi H, Sato N, Saga T, Nakamoto Y, Ishimora Y, Toyama T, Togashi K, Konishi J, Brechbiel MW.
The monoclonal antibody-dendrimer conjugates enable to radiolabel antibody with markedly high specific activity with minimal loss of immunoreactivity.
Eur. J. Nucl. Med. 27: 1334-1339, 2000.
[Journal]
271)  Authors NOTLISTED CLARKE, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott A.
Therapeutic Efficacy of Anti-LewisY Humanised 3S193 (Hu3S193) Radioimmunotherapy in a Breast Cancer Model: Enhanced Activity When Combined with Taxol Chemotherapy.
Clin. Cancer Res. 6: 3128-3621, 2000.
[Journal]
272)  Yordanov AT, Deal K, Garmestani K, Kobayashi H, Herring B, Waldmann TA, Brechbiel MW.
Synthesis and Biodistribution Study of a New 211At-Calix[4]arene Complex.
J. Labelled Compds. Radiopharm. 43: 1219, 1225.
[Journal]
273)  Kobayashi H, Reijnders K, English S, Yordanov AT, Milenic DE, Sowers AL, Citrin D, Krishna MC, Waldmann TA, Mitchell JB, Brechbiel MW.
Application of a Macromolecular Contrast Agent for Detection of Alterations of Tumor Vessel Permeability Induced by Radiation .
Clin. Cancer Res. 10: 7712-7720, 10.
[Journal]
274)  Brechbiel MW.
Low Capacity, non-Internalizing Bindings Sites: the Use of Gadolinium Dendrimers. In "Technetium, Rhenium and Other Metals in Chemistry and Nuclear Medicine 6". (Ed. M. Nicolini and U. Mazzi).
SGE Editoriali, Padova, Italy. 713-716, .
[Journal]
Click Here to View Collapsed Bibliography.

This page was last updated on 11/8/2013.